Patients who are receiving<unk><unk>  therapy should be followed up 2-4 times per year.<unk>  rate usually increases during the first year of treatment, with an average increase of 8-10 cm/year. A slow<unk>  rate more than expected should be investigated to exclude other causes such as hypothyroidism or inflammatory bowel disease.
Growth hormone deficiency secondary prevention
Down syndrome secondary prevention
Delayed puberty secondary prevention
Growth hormone deficiency medical therapy
Down syndrome medical therapy
Androgen insensitivity syndrome secondary prevention
Androgen insensitivity syndrome primary prevention
Renal agenesis medical therapy